ClinicalTrials.gg
CompletedNCT02791269Updated Feb 6, 2017Results posted

A Study of Peginterferon Alfa-2a in Participants With Chronic Hepatitis B Virus (HBV) in an Expanded Access Program

A Phase 4 interventional study of Peginterferon alfa-2a in Hepatitis B, Chronic, sponsored by Hoffmann-La Roche. Completed at 6 sites in New Zealand. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2017-02-06.

Sponsored by Hoffmann-La Roche · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 59 studies testing peginterferon alfa-2a in Hepatitis B, Chronic — 1 open to participants now, 1 under way, none of them phase 3. peginterferon alfa-2a · Hepatitis B, Chronic.

Enrollment
51st of 59
24 · median 114
Started
2006
with 4 others
Phase 4
29 of 59
none open now
Registered
47th of 59
by date
Lead sponsor
22 of 59
Hoffmann-La Roche

Among the 59 studies testing peginterferon alfa-2a in Hepatitis B, Chronic, this one is the 51st largest by enrollment, is one of 5 that started in 2006, is one of 29 in phase 4, and was the 47th registered.

Hepatitis B, Chronic

896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

1 of the 59 studies testing peginterferon alfa-2a in Hepatitis B, Chronic is open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

About peginterferon alfa-2a

peginterferon alfa-2a: first FDA approval 2002 (PEGASYS), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies testing peginterferon alfa-2a in Hepatitis B, Chronic, or all of them as a file.
02

Study summary

This is an expanded access, multicenter, national, open-label, and non-randomized study to analyze the safety of peginterferon alfa-2a in participants with hepatitis B e antigen (HBeAg) positive and HBeAg negative chronic HBV infection. All participants will receive 48 weeks treatment of peginterferon alfa-2a monotherapy, followed by a 24 week treatment-free follow-up period.

03

Conditions studied

  • Hepatitis B, Chronic

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Non-cirrhotic participants
  • surface antigen (HBsAg) positive for at least 6 months
  • Hepatitis B surface antibody (anti-HBs) negative
  • Elevated serum (ALT) greater than (>) (ULN) but less than or equal to (\</=) 10 times of ULN
  • HBeAg positive participants: HBV DNA > 500,000 copies/mL, HBeAg negative participants: HBV DNA >100,000 copies/mL by polymerase chain reaction (PCR)
  • Participants with chronic hepatitis B (CHB) who are treatment-naive
  • No previous antiviral treatment with interferon (IFN: standard or pegylated) or with a nucleoside analogue
  • For women of : negative urine or serum pregnancy test documented within the 24-hour period prior to the first dose of test drug. Willingness to use reliable during the study and for 3 months after treatment completion

Exclusion criteria

Exclusion Criteria:

  • Previous antiviral or IFN-based therapy for CHB before enrolment
  • Pregnant or breast feeding women participants
  • Evidence of decompensated liver disease
  • Co-infection with active hepatitis A, , hepatitis D and/or (HIV)
  • History or other evidence of a medical condition associated with chronic liver disease other than viral hepatitis
  • Previous or current hepatocellular carcinoma
  • History of or other evidence of bleeding from esophageal varices or other conditions consistent with decompensated liver disease
  • Alpha-fetoprotein levels of >100 nanograms (ng)/mL
  • Severe psychiatric disease
  • History of a severe seizure disorder or current anticonvulsant use
  • History of immunologically mediated disease, chronic pulmonary disease associated with functional limitation, severe cardiac disease, major organ transplantation or other evidence of severe illness, , or any other conditions which would make the participant, in the opinion of the investigator, unsuitable for the study
  • Thyroid disease uncontrolled by prescribed medications
  • Evidence of severe retinopathy
  • Alcohol intake more than 3 standard drinks per day for men and 2 standard drinks per day for women
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    HBeAg Negative Participants

    HBeAg negative participants will receive peginterferon alfa-2a 180 micrograms (mcg) subcutaneous (SC) injection once weekly (QW) for 48 weeks followed by a 24 weeks treatment-free follow-up period.

    Drug: Peginterferon alfa-2a

  • Experimental
    HBeAg Positive Participants

    HBeAg Positive participants will receive peginterferon alfa-2a 180 mcg SC injection QW for 48 weeks followed by a 24 weeks treatment-free follow-up period.

    Drug: Peginterferon alfa-2a

Interventions

06

What researchers measure

Primary outcomes

  1. Number of HBeAg Positive Participants With Hepatitis B Virus-deoxy Ribonucleic Acid (HBV-DNA) Less Than (<) 100,000 Copies Per Milliliter (Copies/mL)

    HBV-DNA was assessed in plasma samples using quantitative Roche polymerase chain reaction (PCR) or Taqman tests.

    Time frame: End of 24-weeks follow-up (Week 72)

  2. Number of Participants With HBV-DNA <20,000 Copies/mL

    HBV-DNA was assessed in plasma samples using quantitative Roche PCR or Taqman tests.

    Time frame: End of 24-weeks follow-up (Week 72)

Secondary outcomes

  1. Number of Participants With HBV-DNA <400 Copies/mL

    HBV-DNA was assessed in plasma samples using quantitative Roche PCR or Taqman tests.

    Time frame: Week 48 (end of treatment) and Week 72 (end of follow-up)

  2. Number of Participants With Hepatitis B Surface Antigen (HBsAg) Seroconversion

    HBsAg seroconversion was defined as the absence of HBsAg (a negative result for HBsAg) and the presence of anti-HBs (a positive result for anti-HBs). Both HBeAg positive and negative participants were HBsAg positive at baseline and absence of HBsAg (seroconversion) was analyzed.

    Time frame: Week 48 (end of treatment) and Week 72 (end of follow-up)

  3. Number of Participants With Normalization of Alanine Aminotransferase (ALT) Level

    ALT is an enzyme found mainly in liver and is measured to check if the liver is damaged or diseased. In case of liver damage or disease, the liver releases ALT into the blood stream and the ALT level increases. Normal ALT level = less than upper limit of normal (40 units per liter).

    Time frame: Week 48 (end of treatment) and Week 72 (end of follow-up)

  4. Number of Participants With HBeAg Seroconversion

    HBeAg seroconversion for HBeAg positive participants was defined as the loss of HBeAg (a negative result for HBeAg) and the presence of anti-HBe (a positive result for anti-HBe).

    Time frame: Week 48 (end of treatment) and Week 72 (end of follow-up)

07

Results

Posted Feb 6, 2017

Participant flow

Participant flow — Overall Study
MilestoneHBeAg Negative ParticipantsHBeAg Positive Participants
Started420
Completed419
Not completed01
Withdrew: Lost to follow-up01

Outcome measures

PrimaryNumber of HBeAg Positive Participants With Hepatitis B Virus-deoxy Ribonucleic Acid (HBV-DNA) Less Than (<) 100,000 Copies Per Milliliter (Copies/mL)

HBV-DNA was assessed in plasma samples using quantitative Roche polymerase chain reaction (PCR) or Taqman tests.

Time frame:
End of 24-weeks follow-up (Week 72)
Reported as:
Number · participants
Number of HBeAg Positive Participants With Hepatitis B Virus-deoxy Ribonucleic Acid (HBV-DNA) Less Than (<) 100,000 Copies Per Milliliter (Copies/mL)
participantsHBeAg Positive Participants
Number of HBeAg Positive Participants With Hepatitis B Virus-deoxy Ribonucleic Acid (HBV-DNA) Less Than (<) 100,000 Copies Per Milliliter (Copies/mL)7
PrimaryNumber of Participants With HBV-DNA <20,000 Copies/mL

HBV-DNA was assessed in plasma samples using quantitative Roche PCR or Taqman tests.

Time frame:
End of 24-weeks follow-up (Week 72)
Reported as:
Number · participants
Number of Participants With HBV-DNA <20,000 Copies/mL
participantsHBeAg Negative ParticipantsHBeAg Positive Participants
Number of Participants With HBV-DNA <20,000 Copies/mL03
SecondaryNumber of Participants With HBV-DNA <400 Copies/mL

HBV-DNA was assessed in plasma samples using quantitative Roche PCR or Taqman tests.

Time frame:
Week 48 (end of treatment) and Week 72 (end of follow-up)
Reported as:
Number · participants
Number of Participants With HBV-DNA <400 Copies/mL
participantsHBeAg Negative ParticipantsHBeAg Positive Participants
Week 48 (n=4,18)36
Week 72 (n=3,17)02
SecondaryNumber of Participants With Hepatitis B Surface Antigen (HBsAg) Seroconversion

HBsAg seroconversion was defined as the absence of HBsAg (a negative result for HBsAg) and the presence of anti-HBs (a positive result for anti-HBs). Both HBeAg positive and negative participants were HBsAg positive at baseline and absence of HBsAg (seroconversion) was analyzed.

Time frame:
Week 48 (end of treatment) and Week 72 (end of follow-up)
Reported as:
Number · participants
Number of Participants With Hepatitis B Surface Antigen (HBsAg) Seroconversion
participantsHBeAg Negative ParticipantsHBeAg Positive Participants
Week 48 (n=4,15)00
Week 72 (n=4,13)00
SecondaryNumber of Participants With Normalization of Alanine Aminotransferase (ALT) Level

ALT is an enzyme found mainly in liver and is measured to check if the liver is damaged or diseased. In case of liver damage or disease, the liver releases ALT into the blood stream and the ALT level increases. Normal ALT level = less than upper limit of normal (40 units per liter).

Time frame:
Week 48 (end of treatment) and Week 72 (end of follow-up)
Reported as:
Number · participants
Number of Participants With Normalization of Alanine Aminotransferase (ALT) Level
participantsHBeAg Negative ParticipantsHBeAg Positive Participants
Week 48 (n=4,19)24
Week 72 (n=4,17)47
SecondaryNumber of Participants With HBeAg Seroconversion

HBeAg seroconversion for HBeAg positive participants was defined as the loss of HBeAg (a negative result for HBeAg) and the presence of anti-HBe (a positive result for anti-HBe).

Time frame:
Week 48 (end of treatment) and Week 72 (end of follow-up)
Reported as:
Number · participants
Number of Participants With HBeAg Seroconversion
participantsHBeAg Positive Participants
Week 48 (n=19)6
Week 72 (n=17)6

Adverse events

Collected over Baseline up to end of follow-up period (Approximately 72 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
HBeAg Negative Participants—1/4 (25%)3/4 (75%)
HBeAg Positive Participants—0/20 (0%)7/20 (35%)
Most frequent serious events
Most frequent serious events
EventHBeAg Negative ParticipantsHBeAg Positive Participants
chest painCardiac disorders1/40/20
Most frequent other events
Showing 10 of 14
Most frequent other events
EventHBeAg Negative ParticipantsHBeAg Positive Participants
DepressionNervous system disorders2/41/20
Mood disturbanceNervous system disorders1/41/20
TirednessGeneral disorders1/41/20
RashSkin and subcutaneous tissue disorders1/40/20
Non-productive coughRespiratory, thoracic and mediastinal disorders1/40/20
InsomniaPsychiatric disorders1/40/20
Urinary frequencyRenal and urinary disorders1/40/20
Itchy skinSkin and subcutaneous tissue disorders0/41/20
HypothyroidismEndocrine disorders0/41/20
GlaucomaEye disorders0/41/20

Baseline characteristics

Safety analysis population included participants who received at least one dose of study medication and had one subsequent post baseline safety assessment.

Age, Continuous
Age, Continuous(years)HBeAg Negative ParticipantsHBeAg Positive ParticipantsTotal
Mean43.25 ± 5.7531.57 ± 9.4333.52 ± 9.88
Gender
Gender(Participants)HBeAg Negative ParticipantsHBeAg Positive ParticipantsTotal
Female077
Male41317
08

Study locations

6 sites
  • Auckland, New Zealand
  • Hamilton, New Zealand
  • New Plymouth, New Zealand
  • Riccarton, Christchurch, 8011, New Zealand
  • Rotorua, New Zealand
  • Whangarei, New Zealand
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2006, a primary completion of Jul 2008 and a completion of Jul 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2017, 8 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 31, 2016
First posted
Jun 6, 2016
Start
Jan 2006
Primary completionActual
Jul 2008
CompletionActual
Jul 2008
Results first posted
Feb 6, 2017
Last update
Feb 6, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 6, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02791269
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jun 6, 2016
Start date
Jan 2006
Primary completion
Jul 2008
Completion
Jul 2008
Results posted
Feb 6, 2017
Last update
Feb 6, 2017

Study contacts

Clinical Trials
study chair · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Peginterferon alfa-2a

Start the discussion